

Reporting Title: Ravulizumab, S  
Performing Location: Rochester

Ordering Guidance:  
To measure only serum concentration of ravulizumab, order RAVU / Ravulizumab, Serum.

To measure the impact of ravulizumab on complement activity and its effect on complement blockage, order RAVMP / Ravulizumab Monitoring Panel, Serum which measures the alternative pathway function.

Specimen Requirements:

Patient Preparation: Suggest discontinuing natalizumab at least 4 weeks prior to testing for ravulizumab quantitation in serum. Patient should consult the healthcare provider who prescribed this drug to determine if discontinuation is an option. If not, ok to proceed with testing while taking natalizumab.

Collection Container/Tube:

Preferred: Red top

Acceptable: Serum gel

Submission Container/Tube: Plastic vial

Specimen Volume: 1 mL

Collection Instructions:

1. Draw blood immediately before next scheduled dose.
2. Immediately after specimen collection, place the tube on wet ice.
3. After specimen has clotted on wet ice, centrifuge at 4 degrees C and aliquot serum into a plastic vial.
4. Freeze specimen within 30 minutes of centrifugation. Specimen must be placed on dry ice if not frozen immediately.

Forms:  
[If not ordering electronically, complete, print, and send a Coagulation Test Request](#) (T753) with the specimen.

| Specimen Type | Temperature        | Time    | Special Container |
|---------------|--------------------|---------|-------------------|
| Serum         | Frozen (preferred) | 28 days |                   |
|               | Ambient            | 28 days |                   |
|               | Refrigerated       | 28 days |                   |

Result Codes:

| Result ID | Reporting Name | Type    | Unit   | LOINC®  |
|-----------|----------------|---------|--------|---------|
| 609420    | Ravulizumab, S | Numeric | mcg/mL | 97184-6 |

LOINC® and CPT codes are provided by the performing laboratory.

Supplemental Report:  
No

CPT Code Information:  
80299

Reference Values:

Lower limit of quantitation=5.0 mcg/mL

>175 mcg/mL-Therapeutic concentration for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome